Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Routes of Administration Subcutaneous (standard and only route): Protocols describe rotating between abdomen, thigh, and upper arm, with abdomen typically providing the most consistent absorption
Corneal epithelial migration and re-epithelialization Wound healing phases: Corneal healing involves epithelial cell migration covering defect, proliferation replacing lost cells, and differentiation restoring barrier function
Heterogeneity of growth hormone-dependent lipolytic factors
For this reason, ongoing monitoring is important